These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 3062908

  • 1. [Prostaglandin E1 in decreased arterial perfusion].
    Pilger E, Bertuch H, Stark G, Hönigl K.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):490-5. PubMed ID: 3062908
    [Abstract] [Full Text] [Related]

  • 2. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
    Trifiletti A, Scamardi R, Pizzoleo MA, Sottilotta G, Soraci S, Attinà A, Bagnato L, Barbera N.
    Panminerva Med; 1999 Mar 15; 41(1):15-7. PubMed ID: 10230250
    [Abstract] [Full Text] [Related]

  • 3. [Intra-arterial administration of prostaglandin E1 in occlusive arterial diseases].
    Davidović L, Vranes M, Cernak I, Kostić D, Lovrić A, Sagić D, Lotina S.
    Srp Arh Celok Lek; 1992 Mar 15; 120(1-2):9-14. PubMed ID: 1641706
    [Abstract] [Full Text] [Related]

  • 4. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
    Gianetti J, De Caterina M, De Cristofaro T, Ungaro B, Guercio RD, De Caterina R.
    Am Heart J; 2001 Oct 15; 142(4):733-9. PubMed ID: 11579367
    [Abstract] [Full Text] [Related]

  • 5. Intraarterial prostaglandine E1 in arterial occlusive disease (AOD) stages III and IV.
    Herold A, Bruch HP, Hörl M, Düsel W.
    Prog Clin Biol Res; 1987 Oct 15; 242():439-44. PubMed ID: 2959966
    [Abstract] [Full Text] [Related]

  • 6. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
    Trübestein G, von Bary S, Breddin K, Diehm C, Gruss JD, Heinrich H, Horsch S, Kriessmann A, Maass U, Martin M.
    Vasa Suppl; 1989 Oct 15; 28():44-9. PubMed ID: 2692200
    [Abstract] [Full Text] [Related]

  • 7. Clinical application of prostaglandin E1 in cases of occlusive arterial disease.
    Mishima Y.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Oct 15; 15():547-8. PubMed ID: 2936166
    [Abstract] [Full Text] [Related]

  • 8. Prostaglandin E1 in chronic arterial disease: a multicenter study.
    Trübestein G, Diehm C, Gruss JD, Horsch S.
    Prog Clin Biol Res; 1987 Oct 15; 242():445-51. PubMed ID: 3313418
    [No Abstract] [Full Text] [Related]

  • 9. Intermittent intraarterial infusion therapy with PGE1 in patients with severe claudication--results of a randomized prospective double blind study.
    Caspary L, Creutzig A, Radeke U, Specht S, Alexander K.
    Biomed Biochim Acta; 1988 Oct 15; 47(10-11):S307-10. PubMed ID: 3073766
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K, Rogatti W, Rüttgerodt K.
    Vasa Suppl; 1989 Oct 15; 28():31-8. PubMed ID: 2609242
    [Abstract] [Full Text] [Related]

  • 11. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P, Simmet T, Peskar BA, Reuter H, Sinzinger H, Rogatti W, Tilsner V.
    Wien Klin Wochenschr; 1988 Jul 15; 100(14):477-81. PubMed ID: 3062905
    [Abstract] [Full Text] [Related]

  • 12. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
    Claeys LG, Horsch S.
    Int Angiol; 1996 Dec 15; 15(4):344-9. PubMed ID: 9127776
    [Abstract] [Full Text] [Related]

  • 13. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA, Malatino LS, Santonocito M, Messina R, Attinà T, Dell'Arte S, Sarnataro F.
    Int J Clin Pharmacol Ther; 1999 Jul 15; 37(7):347-51. PubMed ID: 10442509
    [Abstract] [Full Text] [Related]

  • 14. Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
    Leschke M, Schoebel FC, Strauer BE.
    Clin Hemorheol Microcirc; 1997 Jul 15; 17(1):59-66. PubMed ID: 9181759
    [Abstract] [Full Text] [Related]

  • 15. Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD)--a preliminary report on a placebo-controlled double-blind study.
    Diehm C, Stammler F, Hübsch-Müller C, Eckstein HH, Simini B.
    Vasa Suppl; 1987 Jul 15; 17():52-6. PubMed ID: 3551154
    [No Abstract] [Full Text] [Related]

  • 16. [Intravenous PGE-1 in peripheral vascular obstructive disease: use over a 6-month period].
    Llorente Gutiérrez J, González Fernández MA, Fuentes Irigoyen R, Jiménez Caballero E.
    Farm Hosp; 2004 Jul 15; 28(3):188-91. PubMed ID: 15222872
    [Abstract] [Full Text] [Related]

  • 17. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
    MMW Fortschr Med; 2003 Dec 18; 145(51-52):41. PubMed ID: 14974333
    [No Abstract] [Full Text] [Related]

  • 18. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
    Sinzinger H, Rogatti W.
    Wien Klin Wochenschr; 1991 Dec 18; 103(18):558-65. PubMed ID: 1750223
    [Abstract] [Full Text] [Related]

  • 19. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
    Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K.
    Am Heart J; 2003 Feb 18; 145(2):330-3. PubMed ID: 12595852
    [Abstract] [Full Text] [Related]

  • 20. [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].
    Hinderer S, Brachmann R, Nedder KH, Bucher J, Beischer W.
    Vasa; 1991 Feb 18; 20(2):100-8. PubMed ID: 1877328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.